Alkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Alkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'
January 22, 2016 9:40 AM EST
UBS maintained a Neutral rating on Alkermes (NASDAQ: ALKS), and cut the price target to $36.00 (from $65.00). With the failure of FORWARD-3 and FORWARD-4 studies for ALKS 5461 in MDD, UBS believes that there is a very low possibility of getting this product approved even... More
January 21, 2016 12:52 PM EST
Morgan Stanley downgraded Alkermes (NASDAQ: ALKS) from Overweight to Underweight with a price target of $35.00.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
...
More
January 21, 2016 9:51 AM EST
Cowen downgraded Alkermes (NASDAQ: ALKS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.
Shares of Alkermes closed at $60.42 yesterday.
...
More
January 21, 2016 7:03 AM EST
Alkermes plc (Nasdaq: ALKS) announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase 3 efficacy studies to read out from the comprehensive FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients who have an... More
